A 28-year-old woman presents with amenorrhea and galactorrhea for 6 months. Fasting serum prolactin is 85 ng/mL. Dedicated pituitary MRI with dynamic contrast shows a focal hypoenhancing lesion in the right pituitary measuring 7 mm, with stalk deviation to the left (structure **A** in the diagram). Thyroid function and renal function are normal. She denies antipsychotic or metoclopramide use. What is the most appropriate next step in management?
A. Refer for transsphenoidal surgery given the imaging findings of stalk deviation
B. Perform visual field testing and then schedule surgery if any defect is found
C. Initiate cabergoline 0.25–0.5 mg twice weekly and reassess prolactin and clinical response in 4–6 weeks
D. Obtain a PEG precipitation test to rule out macroprolactin before starting dopamine agonist therapy
Explanation
Why Initiate cabergoline 0.25–0.5 mg twice weekly is right
The structure marked A is a hypoenhancing microadenoma (<10 mm) in the right pituitary with stalk deviation — the classic imaging hallmark of a prolactinoma. The clinical presentation (amenorrhea, galactorrhea), biochemistry (prolactin 85 ng/mL in the 25–100 ng/mL range, consistent with a true prolactinoma after ruling out drugs and hypothyroidism), and imaging findings together establish the diagnosis of microprolactinoma. According to the Endocrine Society Guidelines and Harrison's, medical therapy with dopamine agonists is first-line for both micro- and macroprolactinomas. Cabergoline is preferred over bromocriptine due to superior efficacy, tolerability, and tumor shrinkage; >90% of microadenomas normalize prolactin and restore gonadal function. Surgery is reserved for dopamine-agonist intolerance, resistance, or persistent visual deficits — none of which apply here.
Why each distractor is wrong
Refer for transsphenoidal surgery given the imaging findings of stalk deviation: Stalk deviation is an expected imaging finding in prolactinomas and does not mandate surgery. Surgery is reserved for medical therapy failure, intolerance, or mass effect with visual loss. Microadenomas do not cause visual field defects because they remain below the optic chiasm.
Perform visual field testing and then schedule surgery if any defect is found: Visual field loss occurs only with macroadenomas (≥10 mm) that compress the chiasm from below. This patient has a 7 mm microadenoma with an uncompressed chiasm; visual field testing is not indicated and would delay appropriate medical therapy.
Obtain a PEG precipitation test to rule out macroprolactin before starting dopamine agonist therapy: While macroprolactin should be considered in mild hyperprolactinemia (typically <100 ng/mL with few symptoms), this patient's prolactin of 85 ng/mL combined with clear clinical symptoms (amenorrhea, galactorrhea) and imaging confirmation of a microadenoma makes macroprolactinemia unlikely. The PEG test is not a prerequisite before starting therapy in this scenario; it is considered when biochemistry and imaging are discordant.
High-YieldNEET PG
Microprolactinomas are managed medically first-line with dopamine agonists (cabergoline preferred); surgery is reserved for medical failure, intolerance, or persistent mass effect — not for imaging findings alone.
Endocrine Society Hyperprolactinemia Guidelines 2011; Harrison's 21e; Williams Endocrinology
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
